Pfizer And Myovant Get FDA Nod For Myfembree
Pfizer And Myovant Get FDA Nod For Myfembree NEW YORK CITY (dpa-AFX) - Pfizer Inc. and Myovant Sciences announced that the U.S. Food and Drug Administration has approved Myfembree, the first once-daily treatment for heavy menstrual bleeding associated with uterine fibroids. Under the collaboration terms, Myovant and Pfizer will jointly commercialize Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) in the U.S. The drug is expected to be available in June 2021. Myfembree is approved for management of heavy menstrual bleeding associated with uterine fibroids in preme...
Source: finanznachrichten.de